logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11040117 B1

PDFFull Text
Date of Patent:
Jun. 22, 2021

Filed:

Nov. 06, 2018

Treatment of a subtype of asd

Applicant:

Stalicla S.a., Geneva, CH;

Inventor:

Lynn Durham, Geneva, CH;

Assignee:

Stalicla S.A., Geneva, CH;

Attorney:

Millen White Zelano and Branigan, PC

Primary Examiner:

Lianko G Garyu

Int. Cl.
CPC ...
A61K 49/00 (2006.01); A61K 31/26 (2006.01); A61P 25/00 (2006.01); A61K 31/10 (2006.01); A61K 31/155 (2006.01); A61K 31/192 (2006.01); A61K 31/203 (2006.01); A61K 31/343 (2006.01); A61K 31/352 (2006.01); A61K 31/365 (2006.01); A61K 31/375 (2006.01); A61K 31/4409 (2006.01); A61K 31/4425 (2006.01); A61K 36/062 (2006.01); A61K 38/17 (2006.01); A61B 5/16 (2006.01);
U.S. Cl.
CPC ...
A61K 49/0004 (2013.01); A61B 5/167 (2013.01); A61K 31/10 (2013.01); A61K 31/155 (2013.01); A61K 31/192 (2013.01); A61K 31/203 (2013.01); A61K 31/26 (2013.01); A61K 31/343 (2013.01); A61K 31/352 (2013.01); A61K 31/365 (2013.01); A61K 31/375 (2013.01); A61K 31/4409 (2013.01); A61K 31/4425 (2013.01); A61K 36/062 (2013.01); A61K 38/1706 (2013.01); A61K 38/1709 (2013.01); A61P 25/00 (2018.01);
Abstract

The present invention is directed to a pharmaceutical composition comprising an Nrf2-inhibitor. Likewise, the present invention is directed to a pharmaceutical composition for use in the treatment of ASD in a patient, comprising: determining whether the patient suffers from ASD subtype 1 and administering a therapeutically effective amount of an Nrf2-inhibitor if the patients suffers from ASD subtype 1, wherein determining whether the patient suffers from ASD subtype 1 comprises administering the patient an Nrf2-activator and identifying the patient as suffering from ASD subtype 1 if he shows a negative response.

Find Patent Forward Citations

Durham, Lynn. (2021). Treatment of a subtype of asd (U.S. Patent No. 11040117). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11040117

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…